Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography (CINOPSIS CT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00793182
Recruitment Status : Terminated (Slow enrollment)
First Posted : November 19, 2008
Results First Posted : September 29, 2017
Last Update Posted : March 6, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the contrast-induced nephropathy (CIN) rate in subjects randomized to receive either Ioversol or Iodixanol for contrast-enhanced computed tomography.

Condition or disease Intervention/treatment Phase
Renal Impairment Drug: Ioversol 320 mgI/mL Drug: Iodixanol 320 mgI/mL Phase 4

Detailed Description:
Contrast-induced nephropathy (CIN) is an acute decline in renal function after the administration of iodinated contrast agents. CIN is commonly defined as an increase in post contrast serum creatinine (SCr) greater than or equal to 25% or an absolute increase greater than or equal to 0.5 mg/dL from pre contrast baseline values. Study will evaluate and compare the effects of two (2) contrast media products on renal function in subjects with stable reduced renal function while undergoing contrast-enhanced computed tomography.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-enhanced Computed Tomography
Study Start Date : January 2009
Actual Primary Completion Date : June 2009
Actual Study Completion Date : June 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Ioversol 320 mgI/mL
Drug: Ioversol 320 mgI/mL
125 mL of Ioversol administered in the vein
Other Name: Optiray

Active Comparator: 2
Iodixanol 320 mgI/mL
Drug: Iodixanol 320 mgI/mL
125 mL of Iodixanol administered in the vein
Other Name: Visipaque

Primary Outcome Measures :
  1. Percentage of Patients With Contrast-induced Nephropathy (CIN) [ Time Frame: Based on the SCr values of each patient measured from 2 to 24 hours before and from 48 to 72 hours after contrast medium administration ]

    Contrast-induced nephropathy (CIN) is defined as an increase of ≥ 25% or an increase of ≥ 0.5 mg/dL from baseline serum creatinine (SCr), within 48 - 72 hours after contrast medium administration.

    For each patient, SCr values were measured from 2 to 24 hours before and from 48 to 72 hours after contrast medium administration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females 18 years of age or older
  • Subjects scheduled for a clinically indicated CECT requiring 40 grams of iodine (125 mL)
  • Subjects have an abnormal screening SCr that results in a calculated eGFR of < 60 mL/min/1.73 m2 using the MDRD formula and acute causes for an elevation in SCr have been excluded
  • Subjects have stable reduced renal function which is defined as an abnormal screening SCr measurement with a < 15% difference from the oldest historical SCr measurement obtained within the proceeding 1 week to 12 weeks
  • Subjects must provide written consent and agree to abide by the site and study requirements

Exclusion Criteria:

  • Subjects previously entered into this study
  • Subjects on dialysis
  • Subjects received any investigational drug within 30 days of contrast administration or participated in an investigational study within 30 days prior to study enrollment
  • Subjects have undergone a procedure using iodinated or gadolinium contrast agent within 7 days prior to contrast administration, or is scheduled to receive additional doses of contrast agents during the 48-72 hour post-study contrast administration
  • Subjects in acute renal failure or have one or more known causes of acute renal failure
  • Subjects have known or suspected unstable renal function
  • Subjects scheduled for a surgical intervention or other procedure within 72 hours after the contrast administration
  • Subjects taking NSAIDs (with the exception of ASA) and/or any type of diuretics who cannot discontinue these drugs post contrast administration and hold all subsequent doses until the 48-72 hour post contrast SCr has been drawn
  • Subjects taking aminoglycosides
  • Subjects known to have an organ transplantation
  • Subjects have severe congestive heart failure (Class III-IV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00793182

Layout table for location information
United States, Alabama
UAB Hospital
Birmingham, Alabama, United States, 35233
United States, Arizona
Radiology LTD
Tucson, Arizona, United States, 85711
United States, District of Columbia
Providence Hospital
Washington, District of Columbia, United States, 20017
United States, Illinois
Methodist Medical Center of Illinois
Peoria, Illinois, United States, 61602
United States, Maine
Maine Research Associates
Auburn, Maine, United States, 04210
United States, Michigan
Genesys Regional Medical Center
Grand Blanc, Michigan, United States, 48439
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 114642
United States, North Carolina
Wake Research Associates
Raleigh, North Carolina, United States, 27612
United States, Ohio
Radiology Consultants, Inc.
Youngstown, Ohio, United States, 44512
United States, Pennsylvania
Geisinger Medical Center
Danville, Pennsylvania, United States, 17822
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States, 19141
United States, Texas
Trinity Clinic
Tyler, Texas, United States, 75701
Sponsors and Collaborators
Layout table for investigator information
Study Director: Eddie Darton, MD Mallinckrodt

Layout table for additonal information
Responsible Party: Guerbet Identifier: NCT00793182    
Other Study ID Numbers: 1323-07-872
First Posted: November 19, 2008    Key Record Dates
Results First Posted: September 29, 2017
Last Update Posted: March 6, 2019
Last Verified: February 2019
Keywords provided by Guerbet:
Contrast Induced Nephropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases